Results 91 to 100 of about 46,038 (143)

Different treatments for Crohn's disease complicated by severe acute lower gastrointestinal bleeding: infliximab therapy is critical and cannot be ignored. [PDF]

Front Pharmacol
Yao S, Wang Z, Xie M, Wu S, Feng Y, Liu X, Wang F.   +6 more
europepmc   +1 more source

An Immune Microenvironment-Integrated Intestinal-on-a-Chip Model for Investigating Immunopathogenesis in Inflammatory Bowel Disease. [PDF]

Molecules
Ying S, Xu H, Xu Y, Mi X.
europepmc   +1 more source

Irritable Bowel Syndrome Prevalence in Patients with Inflammatory Bowel Disease in Remission: Single-Center Experience. [PDF]

Clin Exp Gastroenterol
Golubovic O, Knezevic Ivanovski T, Kralj D, Mitrovic M, Milić A, Svorcan P, Markovic S.   +6 more
europepmc   +1 more source

Infliximab-induced lupus with recurrent pericarditis: longitudinal CMR assessment of inflammatory resolution. [PDF]

Int J Cardiovasc Imaging
Mendpara V, El Roumi J, Klein A.
europepmc   +1 more source

A mathematical model to simulate the biological action of Infliximab on TNF- α in patients with Inflammatory Bowel Disease: the critical role of drug clearance. [PDF]

Bull Math Biol
Portillo AM, De Prado Á, Soares AJ.
europepmc   +1 more source

Hepatic Sarcoidosis Unmasked by Chronic Pruritus and Esophageal Varices: A Case Report. [PDF]

Clin Case Rep
Zheng M, Saadalla K, Sharma S.
europepmc   +1 more source

Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan. [PDF]

J Pharm Policy Pract
Mamiya H, Fukasawa T, Kawakami K.
europepmc   +1 more source

Efficacy and safety of the interleukin-10-fragment F8 fusion protein PF-06687234 as add-on therapy to infliximab in patients with active ulcerative colitis: a randomized, phase IIa clinical trial. [PDF]

Ther Adv Gastroenterol
Schreiber S, Danese S, Vermeire S, Leong RW, Pradhan V, Singh RSP, Yu D, Messing D, Neubert H, Palandra J, Tehlirian C, Gale JD.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Infliximab

Dermatologic Therapy, 2004
Infliximab is a chimeric monoclonal antibody that interferes with the actions of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). Clinical trials of infliximab have demonstrated a rapid and substantial response in patents with psoriasis and psoriatic arthritis, substantiating the role of TNF-alpha in the immunopathogenesis of ...
Laura S, Winterfield, Alan, Menter
openaire   +3 more sources